Randomized, Open‐Label, Single‐Dose, Parallel‐Group Pharmacokinetic Study of PF‐06410293 (adalimumab‐afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syrin...

por Cox, Donna S., Alvarez, Daniel F., Bock, Amy E., Cronenberger, Carol L.
Publicado 2021

Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis

por Kay, Jonathan, Bock, Amy E, Rehman, Muhammad, Zhang, Wuyan, Zhang, Min, Iikuni, Noriko, Alvarez, Daniel F
Publicado 2022

Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a...

por Fleischmann, Roy M, Alvarez, Daniel F, Bock, Amy E, Cronenberger, Carol, Vranic, Ivana, Zhang, Wuyan, Alten, Rieke
Publicado 2021

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®)...

por Fleischmann, Roy M., Alvarez, Daniel F., Bock, Amy E., Cronenberger, Carol, Vranic, Ivana, Zhang, Wuyan, Alten, Rieke
Publicado 2021

Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis

por Fleischmann, Roy M., Bock, Amy E., Zhang, Wuyan, Godfrey, Charles M., Vranic, Ivana, Cronenberger, Carol, Dokoupilová, Eva
Publicado 2022

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

por Fleischmann, Roy M., Alten, Rieke, Pileckyte, Margarita, Lobello, Kasia, Hua, Steven Y., Cronenberger, Carol, Alvarez, Daniel, Bock, Amy E., Sewell, K. Lea
Publicado 2018